title: A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.
authors.affiliation: Department of Allergy and Clinical Immunology, Cleveland Clinic, Respiratory Institute, Cleveland, Ohio. Electronic address: langd@ccf.org.
authors.forename: David M
authors.initials: DM
authors.lastname: Lang
mesh_terms: D000799:Angioedema / Q000188:drug therapy*; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015550:Cell Degranulation / Q000187:drug effects; D002908:Chronic Disease; D017277:Drug Approval; D004351:Drug Resistance; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D007073:Immunoglobulin E / Q000276:immunology*; D000069444:Omalizumab; D016032:Randomized Controlled Trials as Topic; D017455:Receptors, IgE / Q000378:metabolism; D012008:Recurrence; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D006633:Histamine Antagonists; D017455:Receptors, IgE; D000069444:Omalizumab; D007073:Immunoglobulin E